Cumulus Neuroscience Commences Clinical Studies of Digital Biomarker Platform in Degenerative Neurological Diseases

Belfast, UK – 25 May 2022. Cumulus Neuroscience, a global digital health company, announces the start of two validation trials – CNS-101 and CNS-102 – supported by a group of leading global pharma companies and Innovate UK. The studies will investigate the potential benefits of Cumulus’ integrated physiological and digital biomarker platform in quantifying cognitive decline over time in patients with dementia, across AD, ALS and FTD.
More info >>